Neurogene Prices $125M Public Offering at $30/Share
NGNE has more than doubled off its 52-week low of $14.65.
Summary
Neurogene has priced its public offering of 3.5 million shares at $30 per share, raising $125 million. This follows the proposed offering announced yesterday and comes after the company reported highly positive long-term Phase 1/2 clinical data for its NGN-401 gene therapy on June 29. The $125 million capital raise is substantial relative to the company's size, indicating significant dilution for current shareholders. While dilutive, this financing provides critical funds for the development and pre-commercial activities of its lead gene therapy, leveraging the recent positive clinical trial results.
At the time of this announcement, NGNE was trading at $30.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $497M. The 52-week trading range was $14.65 to $37.27. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.